现成预装内分支装置用于紧急胸腹主动脉瘤腔内修复:意大利E-nside腔内移植物分支注册研究结果
该研究基于意大利多中心前瞻性注册研究(INBREED,2020—2024年),纳入64例(34.5%)接受E-nside现成预装内分支装置紧急治疗的胸腹主动脉瘤患者。30天主要不良事件累积发生率为28%,死亡5例(9.1%),脊髓缺血率为8%(n=5),术后卒中1例(1.6%);249条目标血管中97.2%经内分支成功桥接,1年目标血管不稳定免除率为93%±3%。作者认为E-nside是紧急治疗胸腹主动脉瘤的有效方案,但需进一步研究评估其临床作用。
要点
- 64例紧急胸腹主动脉瘤患者接受E-nside现成预装内分支装置治疗,30天死亡率为9.1%(5例)。
- 30天主要不良事件累积发生率为28%,脊髓缺血率为8%(n=5),术后卒中1例(1.6%)。
- 249条目标血管中97.2%经内分支成功桥接,1年目标血管不稳定免除率为93%±3%。
核心结论
- E-nside是紧急治疗胸腹主动脉瘤(包括有症状、破裂及无法等待定制装置的大无症状胸腹主动脉瘤)的有效方案。
- 预装内分支及可用的近端和远端移植物直径在紧急情况下可能有用,在移植物和目标血管稳定性方面提供了满意的早期和1年结果。
- 需要进一步研究评估E-nside在紧急胸腹主动脉瘤修复中的临床作用。
研究设计与样本
- 本研究为医师发起的全国多中心注册研究(INBREED),前瞻性收集2020—2024年接受E-nside腔内移植物治疗的患者数据,仅纳入紧急病例。
- 共纳入64例(占INBREED注册185例的34.5%)紧急治疗的胸腹主动脉瘤患者。
- 紧急修复原因:动脉瘤相关症状31例(48.4%),包裹性破裂8例(12.5%),大动脉瘤>80 mm 25例(39.1%)。
- 修复范围I~III型32例(50%),IV型32例(50%);18例(28%)有狭窄(<25 mm)的旁内脏主动脉管腔。
- 29例(45.3%)置入辅助近端胸主动脉移植物,33例(51.5%)使用远端分叉腹主动脉移植物。
主要发现
- 249条目标血管(97.2%)经内分支成功桥接,入路为上臂(81.2%)或股动脉(18.8%)。
- 目标血管使用球囊扩张支架184条(75.7%),自膨式支架59条(24.3%);每條目标血管桥接平均时间为39.9±28.4分钟。
- 30天主要不良事件累积发生率为28%,死亡5例(9.1%)。
- 术后卒中1例(1.6%),脊髓缺血率为8%(n=5)。
- 249条经内分支成功桥接的目标血管中,1年目标血管不稳定免除率为93%±3%。
临床怎么用
- 作者认为E-nside是紧急治疗胸腹主动脉瘤的有效方案,包括有症状和破裂的胸腹主动脉瘤,以及无法等待定制装置的大无症状胸腹主动脉瘤。
- 作者认为预装内分支及可用的近端和远端移植物直径在紧急情况下可能有用,并提供了满意的早期和1年结果。
- 作者提出需要进一步研究评估E-nside在紧急胸腹主动脉瘤修复中的临床作用。
局限性
- 需要进一步研究评估E-nside在紧急胸腹主动脉瘤修复中的临床作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to report the outcomes of endovascular urgent thoracoabdominal aortic (TAAA) repair, using an off-the-shelf preloaded inner branch device (E-nside; Artivion). METHODS: Data from a physician-initiated national multicenter registry, including patients treated with E-nside endograft (INBREED) were prospectively collected (2020-2024); only urgent cases were included in this study. Primary outcomes were technical success and mortality at 30 days. Secondary outcomes were spinal cord ischemia rate, stroke rate, major adverse events (MAE) as also branch instability at 12 months. RESULTS: Of 185 patients enrolled in the INBREED, 64 (34.5%) were treated in a urgent setting and were included in the study. Reason for urgent repair was presence of aneurysm-related symptoms in 31 patients (48.4%), a contained rupture in eight (12.5%), and a large aneurysm >80 mm in 25 (39.1%). Extent of repair was I to III in 32 patients (50%) and IV in 32 (50%); 18 (28%) had a narrow (<25 mm) paravisceral aortic lumen. An adjunctive proximal thoracic endograft was deployed in 29 patients (45.3%); a distal bifurcated abdominal endograft was used in 33 (51.5%). Two hundred forty-nine target vessels (97.2%) were successfully incorporated through an inner branch from an upper arm (81.2%) or femoral (18.8%) access. A balloon expandable stent was used in 184 (75.7%) target vessels, a self-expandable stent in 59 (24.3%). Mean time for target vessel bridging was 39.9 ± 28.4 minutes per target vessel. Thirty-day cumulative major adverse event (MAE) rate was 28%, and mortality occurred in five patients (9.1%). There was one postoperative stroke (1.6%), and the spinal cord ischemia (SCI) rate was 8% (n = 5). For the 249 target vessels successfully incorporated through an inner branch, 1-year freedom from target vessel instability was 93% ± 3% after 1 year. CONCLUSIONS: The E-nside represents a valid solution for the urgent treatment of TAAAs, including symptomatic and ruptured TAAAs, as well as large asymptomatic TAAAs that cannot wait for a custom-made device. The preloaded inner branches and available proximal and distal graft diameters might be useful in urgent settings and provided satisfactory early and 1-year results, in terms of both endograft and target vessel stability. Further studies are required to assess the clinical role of E-nside for urgent TAAA repair.
引用
- Piazza M, Squizzato F, Ferri M, et al. Outcomes of off-the-shelf preloaded inner branch device for urgent endovascular thoraco-abdominal aortic repair in the ItaliaN Branched Registry of E-nside EnDograft. J Vasc Surg. 2024. PMID: 38908806. doi:10.1016/j.jvs.2024.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。